Quantum Genomics to give an exclusive license for firibastat in Greater China region, including Hong…
Quantum Genomics Reports First Half 2020 Financial Results
Quantum Genomics Reports First Half 2020 Financial Results and Provides Corporate Update Read the press…
Quantum Genomics to give an exclusive license for firibastat in South-East Asia, Australia and New Zealand
Quantum Genomics to give an exclusive license for firibastat in South-East Asia, Australia and New…
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
The FRESH study is a randomized, double-blind, placebo-controlled pivotal phase III study, which will be…
Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients
Firibastat could be used in hypertensive and heart failure patients with concomitant renal dysfunction, subject…
Quantum Genomics Provides Update on the Impact of the COVID-19 Health Crisis on Clinical Research Activities
Together with their partners, Quantum Genomics is taking all necessary measures to maintain its clinical development…
Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights
Given the current public health crisis, and in order to prepare for its financial consequences,…
Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing…
Quantum Genomics to present at the 2020 Gordon Conference
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing…